| Impact of co-enrollment | Trial A | Trial B |
---|---|---|---|
Scientific integrity | |||
 Intervention-related | |||
  1. Population of concern | Overlap? |  |  |
  2. Enrollment window | Which closes first? |  |  |
  3. Timing of intervention | Overlap? |  |  |
  4. Study period | Overlap? |  |  |
  5. Exclusion criteria | Conflict? |  |  |
 Overlapping endpoints | |||
  6. Primary endpoint | Overlap? |  |  |
Potential impact? | |||
  7. Secondary and exploratory endpoints | Overlap? |  |  |
Potential impact? | |||
 Other | |||
  8. Magnitude of interaction | Known/unknown? |  |  |
Dilution/enhancement of effect? | |||
  9. Level of randomization | Same/different? |  |  |
  10. Timing of randomization | Same/different? |  |  |
  11. Potential of imbalance | Yes/no? |  |  |
  12. Effect of co-enrollment | Contamination? |  |  |
Data interpretation | |||
  13. Power to determine interactions | Sufficient/insufficient? |  |  |
  14. Attribution of adverse events | Easy/difficult? |  |  |
Feasibility/burden | |||
  15. Parent/legal guardian burden | Yes/no? |  |  |
  16. Site investigator burden | Yes/no? |  |  |
  17. Bedside clinical team burden | Yes/no? |  |  |
  18. Current sharing scheme | Yes/no? |  |  |
Additional considerations | |||
  19. Impact on publication | Known/unknown? |  |  |
  20. Intervention use off-protocol | Yes/no? |  |  |
  21. Priority | High/low? |  |  |
  22. Possible sharing arrangement |  |